See more : Medicale Corp (MCLE) Income Statement Analysis – Financial Results
Complete financial analysis of Stem Holdings, Inc. (STMH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Stem Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Cruz Battery Metals Corp. (CRUZ.CN) Income Statement Analysis – Financial Results
- Photocure ASA (PHO.OL) Income Statement Analysis – Financial Results
- Western Uranium & Vanadium Corp. (WUC.CN) Income Statement Analysis – Financial Results
- BHP Group Limited (BHPLF) Income Statement Analysis – Financial Results
- G&P Acquisition Corp. (GAPAW) Income Statement Analysis – Financial Results
Stem Holdings, Inc. (STMH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://stemholdings.com
About Stem Holdings, Inc.
Stem Holdings, Inc. operates as a vertically-integrated cannabis products and technology company. It engages in the production, distribution, and sale of cannabis and cannabis-infused products. The company's brands include TJ's Gardens, TravisxJames, and Yerba Buena flower and extracts; Cannavore edible confections; Doseology, a CBD mass-market brand; and delivery-as-a-service brands of Budee and Ganjarunner e-commerce platforms. As of September 30, 2021, it had ownership interests in 29 state issued cannabis licenses, including 9 licenses for cannabis cultivation; 3 licenses for cannabis processing; 2 licenses for cannabis wholesale distribution; 3 licenses for hemp production; 7 cannabis dispensary licenses; and 5 licenses for adult-use medical retailers. The company was incorporated in 2016 and is headquartered in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 16.56M | 35.77M | 13.97M | 2.45M | 1.30M | 326.04K | 0.00 |
| Cost of Revenue | 0.00 | 14.44M | 28.18M | 10.31M | 1.94M | 7.56M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 2.12M | 7.59M | 3.67M | 516.00K | -6.26M | 326.04K | 0.00 |
| Gross Profit Ratio | 0.00% | 12.82% | 21.21% | 26.25% | 21.05% | -483.44% | 100.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.64M | 14.48M | 22.96M | 13.33M | 19.29M | 8.86M | 2.78M | 87.70K |
| Selling & Marketing | 103.00K | 266.00K | 368.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.75M | 14.48M | 22.96M | 13.33M | 19.29M | 8.86M | 2.78M | 87.70K |
| Other Expenses | 0.00 | 1.97M | 2.30M | 0.00 | -40.00K | 44.39K | 0.00 | 0.00 |
| Operating Expenses | 3.75M | 14.48M | 22.96M | 13.33M | 19.29M | 8.86M | 2.78M | 87.70K |
| Cost & Expenses | 3.75M | 28.92M | 51.14M | 23.64M | 21.22M | 8.86M | 2.78M | 87.70K |
| Interest Income | 0.00 | 650.00K | 1.95M | 2.43M | 2.59M | 440.00 | 5.22K | 0.00 |
| Interest Expense | 1.24M | 650.00K | 1.88M | 2.43M | 2.59M | 345.66K | 975.00 | 0.00 |
| Depreciation & Amortization | -156.29K | 2.49M | 2.24M | 2.37M | 1.23M | 1.36M | 129.22K | 263.10K |
| EBITDA | -3.90M | -7.90M | -2.92M | -6.74M | -25.22M | -7.04M | -2.75M | -87.70K |
| EBITDA Ratio | 0.00% | -47.68% | -22.13% | -54.05% | -984.54% | -474.75% | -711.38% | 0.00% |
| Operating Income | -3.75M | -12.36M | -15.37M | -9.67M | -18.77M | -7.56M | -2.75M | -87.70K |
| Operating Income Ratio | 0.00% | -74.61% | -42.98% | -69.17% | -765.89% | -583.44% | -843.73% | 0.00% |
| Total Other Income/Expenses | -1.39M | -10.14M | 3.37M | -1.83M | -6.92M | -301.00K | 4.24K | -175.40K |
| Income Before Tax | -5.13M | -16.62M | -64.61M | -11.49M | -28.99M | -7.86M | -2.75M | -87.70K |
| Income Before Tax Ratio | 0.00% | -100.32% | -180.62% | -82.25% | -1,182.58% | -606.66% | -842.43% | 0.00% |
| Income Tax Expense | 0.00 | 10.78M | 3.71M | 1.69M | -7.69M | 44.83K | 975.00 | -263.10K |
| Net Income | -19.02M | -27.40M | -68.32M | -13.18M | -21.30M | -7.86M | -2.75M | -87.70K |
| Net Income Ratio | 0.00% | -165.40% | -190.99% | -94.34% | -868.87% | -606.66% | -842.43% | 0.00% |
| EPS | -5.92 | -12.11 | -42.88 | -21.92 | -75.40 | -94.64 | -49.07 | -3.27 |
| EPS Diluted | -5.92 | -12.11 | -42.88 | -21.92 | -75.40 | -94.64 | -49.07 | -3.27 |
| Weighted Avg Shares Out | 2.53M | 2.26M | 1.59M | 601.43K | 282.45K | 83.05K | 55.97K | 26.85K |
| Weighted Avg Shares Out (Dil) | 2.53M | 2.26M | 1.59M | 601.43K | 282.45K | 83.05K | 55.97K | 26.85K |
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT
Cell Culture Market to Reach USD 44,593.1 million by 2034 amid Growing Demand for Biopharmaceuticals and Advances in Stem Cell Culture Techniques | Future Market Insights, Inc.
New-age Vaccines Warrant Wide Applicability of Cell Culture! FMI Predicts Favorable Forecast Period for Key Players Despite Waning CAGR. Cell culture is used in the pharmaceutical and biotechnology industries, diagnostic laboratories, and research institutes for applications such as drug discovery...
Naples Soap Company to Integrate Revolutionary NASA Stem Cell Technology into its New Skincare Line
NAPLES, Fla.--(BUSINESS WIRE)---- $NASO #naplessoap--Naples Soap Company to Integrate Revolutionary NASA Stem Cell Technology into its New Skin care Line.
Automotive Valve Stem Seal Market Valuation to Reach USD 866.5 Million by 2034, Driven by Continued Growth in Automotive Industry and Technological Advancements | Future Market Insights Inc.
The United States remains a highly lucrative market for automotive valve stem seal manufacturers. According to the latest analysis, demand for automotive valve stem seals in the USA is projected to grow at a 3.7% CAGR during the assessment period,...
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development
City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory...
CSE Bulletin: Suspension - Stem Holdings Inc. (STEM)
Toronto, Ontario--(Newsfile Corp. - Le 1 mars/March 2024) - Effective immediately, Stem Holdings Inc. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules.
CSE Bulletin: Consolidation - Stem Holdings Inc. (STEM)
Toronto, Ontario--(Newsfile Corp. - Le 5 février/February 2024) - Stem Holdings Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every one hundred (100) pre-consolidated common shares....
Stem Holdings, Inc. Announces Clarification Regarding Effective Date of Reverse Share Split on the Canadian Securities Exchange
BOCA RATON, FL, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Stem Holdings, Inc. (the “Company” or “Stem”) (OTC Pink: STMH CSE: STEM), a vertically-integrated cannabis branded products and technology company, at the request of CIRO, announces today a clarification with respect...
Stem Holdings, Inc. Announces Effectiveness of Reverse Stock Split on February 1, 2024.
BOCA RATON, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Stem Holdings, Inc. (the “Company” or “Stem”) (OTC Pink: STMH CSE: STEM), a vertically-integrated cannabis branded products and technology company, announced that the February 1, 2024 effectiveness of its one for...
Source: https://incomestatements.info
Category: Stock Reports